Xinhua medical Clarity and not qingyue description of the black and German companies or involved in tax evasion

"The Securities Market weekly Red weekly" author Tian Gang Red Weekly published "Xinhua Medical: To buy a large number of biological income can not support the" article, pointed out that the Anglo-German biological disclosure of sales data from the client state and the pharmaceutical industry issued by the financial data to be corresponding. In this connection, Xinhua medical on July 1 issued a clarification bulletin, trying to explain the company disclosed the relevant data is correct, and customer data is not different. However, the company's explanation is difficult to withstand scrutiny, the specific data is "more and more black" suspicion, which makes us further suspect that the Xinhua medical and Anglo-German companies and Shanghai Levin's subsidiary of the State and the pharmaceutical industry, there must be one side is lying, the disclosure of financial data there is a huge amount of artificial adjustment, At the same time, Anglo-German companies also have problems in paying taxes. Anglo-German company PK state and pharmaceutical industry, who is lying? Xinhua Medical Service in the clarification of the announcement, "as of December 31, 2012, the Anglo-German company received the above Project project payment of 26.6575 million yuan, are recognized as an advance accounts." Anglo-German companies in March 2013, June, respectively, the completion of the project completed the acceptance certificate, according to the Anglo-German company's revenue recognition principle, the company 2013 confirmed that the project operating income of 41.1 million yuan. As of December 31, 2013, the company has received the above Project project payment of 39.045 million yuan, the balance of accounts receivable is 2.055 million yuan. As of April 2014, the company has received all of the above items (including the project warranty). "According to the Xinhua medical description of this section, we can outline the state and the pharmaceutical industry to receive the work of the time period: 2012 received 26.6575 million yuan, at this time the project is still in the construction phase, has not been confirmed by the state and the drug industry acceptance; 2013 years received 12.3875 million yuan ( 39.045 million yuan-26.6575 million yuan), the project was accepted by the state and pharmaceutical industry and recognized as operating income; 2014 received the balance of 2.055 million yuan. Let's take a look at the financial position of the company and the state and the living, which is attributable to the end of 2012. According to the new accounting standards for construction engineering Outsourcing Related Financial accounting regulations, State and biological financial staff need to determine whether the risk of fixed assets has begun to transfer to the company, and as a condition of asset recognition. Under normal circumstances in terms of the specific financial operations of the enterprise, the construction project in the stage of acceptance through the investment department, and has entered the construction, installation, commissioning phase, can be used as the accounting time of construction projects. Prior to this, in the absence of risk transfer of construction advances, that is, not completed the project acceptance, in accordance with the provisions of the contract can only be prepaid (or prepaid works) accounting. In this regard, it is clearly stated in the new Accounting Standards Guide Appendix-Accounting account and main account processing 1123-that "the enterprise will pay for the works in advance of the construction work, and also in this subject." From this part of the content can be judged, at the end of 2012, the company for the state and biological construction projects, has not been accepted by the State and the biological side, soIt is not a problem for Anglo-German companies to account for the advance accounts. The problem, however, is that States and organisms, which should be accounted for under the prepayment account, mean that states and creatures should have a 26.6575 million-dollar prepaid claim against Anglo-German companies by the end of 2012. But according to the Shanghai Wallace Audit report released in July 2013 in the acquisition of state and biological processes, as of the end of 2012, the state and the pharmaceutical industry, the total amount of prepaid account is only 11.9282 million yuan, compared with the above mentioned only to the Anglo-German company's theory of advances in the sum of money. If the data and information disclosed by the Anglo-German company is accurate, it will undoubtedly mean that the state and the pharmaceutical industry have identified the huge project assets in advance, which side of the financial data is the right one for Anglo-German and the state and the pharmaceutical industry? And which company lied in the audit report? Since then, according to Xinhua Medical clarification announcement information, in March 2013 state and the pharmaceutical industry confirmed 40.4 million Yuan project has been inspected, and another 700,000 Yuan project until June 2013 was accepted. It can be inferred that, at the end of April 2013, when the state and the pharmaceutical industry issued audit reports, the company should have carried the vast majority of the project into the "under construction" subject, there should be no large prepaid accounts. In fact, however, according to the data disclosed in the State and pharmaceutical audit reports of Table 3, as at this point, the state and the drug against the Anglo-German companies still have more than 8 million yuan in the prepaid, which is the situation described by the Anglo-German company again a big difference. To sum up, we can think that up to the end of April 2013, the state and the pharmaceutical industry for the construction of the project has been approved by the Department is not so much, this may mean that the Anglo-German disclosure of the project acceptance of the time there is a certain error, which leads to the company in advance to confirm the Anglo-German company suspected of tax evasion? In addition, Xinhua medical clarification in the announcement of the disclosure of the data is also very intriguing: Anglo-German company the project contract amount and final operating income is exactly the same, are 41.1 million yuan; at the same time, from the actual collection of business receipts, the final cash settlement amount is also 41.1 million yuan ( 2013 at the end of the total received project project 39.045 million yuan, the balance of accounts receivable is 2.055 million yuan. That is, the confirmation amount of the operating income is exactly the same as the actual cash settlement amount. According to the information disclosed in the biological audit report of the UK and Germany, the company engaged in the construction business needs to pay VAT sales tax in accordance with the normal ratio of 17%, which is reflected as an ad valorem tax, in the form of a special VAT invoice to the customer to collect cash. This means that for the same construction project, the actual amount of funds received by the Anglo-German company should be greater than the amount that is ultimately recognized as operating income, the difference being part of VAT. But where did the VAT go? From the Xinhua medical Clarification Bulletin data, there is no additional value-added tax on the German life of the part, this is not very strange? Is the company not responding to thisProject to the state and the pharmaceutical industry to issue value-added tax invoices, and then suspected of tax evasion?